M Korbling

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. doi request reprint Twenty-five years of peripheral blood stem cell transplantation
    Martin Korbling
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Blood 117:6411-6. 2011
  2. doi request reprint Fusion of circulating blood cells with solid-organ tissue cells in clinical stem cell transplants: a potential therapeutic model?
    Martin Korbling
    University of Texas, Department of Stem Cell Transplantation and Cellular Therapy, Unit 423, M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Regen Med 3:157-64. 2008
  3. ncbi request reprint Recombinant human granulocyte-colony-stimulating factor-mobilized and apheresis-collected endothelial progenitor cells: a novel blood cell component for therapeutic vasculogenesis
    Martin Korbling
    Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Transfusion 46:1795-802. 2006
  4. ncbi request reprint Adult stem cells for tissue repair - a new therapeutic concept?
    Martin Kørbling
    Department of Blood and Marrow Transplantation, University of Texas M D Anderson Cancer Center, Houston 77030, USA
    N Engl J Med 349:570-82. 2003
  5. ncbi request reprint Hepatocytes and epithelial cells of donor origin in recipients of peripheral-blood stem cells
    Martin Korbling
    Departments of Blood and Marrow Transplantation, University of Texas M D Anderson Cancer Center, Houston 77030, USA
    N Engl J Med 346:738-46. 2002
  6. ncbi request reprint Donor lymphocyte apheresis for adoptive immunotherapy compared with blood stem cell apheresis
    M Korbling
    The University of Texas M D Anderson Cancer Center, Division of Medicine, Department of Blood and Marrow Transplantation, Houston, Texas 77030, USA
    J Clin Apher 16:82-7. 2001
  7. ncbi request reprint Peripheral blood stem cell versus bone marrow allotransplantation: does the source of hematopoietic stem cells matter?
    M Korbling
    Department of Blood and Marrow Transplantation, University of Texas MD Anderson Cancer Center, Houston 77030, USA
    Blood 98:2900-8. 2001
  8. ncbi request reprint Allogeneic transplantation for recurrent or refractory non-Hodgkin's lymphoma with poor prognostic features after conditioning with thiotepa, busulfan, and cyclophosphamide: experience in 44 consecutive patients
    K van Besien
    Department of Hematology, University of Texas, M D Anderson Cancer Center, Houston, USA
    Biol Blood Marrow Transplant 3:150-6. 1997
  9. ncbi request reprint Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies
    I F Khouri
    Department of Hematology, University of Texas M D Anderson Cancer Center, Houston 77030, USA
    J Clin Oncol 16:2817-24. 1998
  10. ncbi request reprint Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma
    I F Khouri
    Department of Hematology, The University of Texas, M D Anderson Cancer Center, Houston 77030, USA
    J Clin Oncol 16:3803-9. 1998

Collaborators

Detail Information

Publications31

  1. doi request reprint Twenty-five years of peripheral blood stem cell transplantation
    Martin Korbling
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Blood 117:6411-6. 2011
    ..Clinical trials comparing the outcome of PBSCT with BM transplantation, registry data analyses, and the role of the National Marrow Donor Program (NMDP) in promoting unrelated blood stem-cell donation are addressed...
  2. doi request reprint Fusion of circulating blood cells with solid-organ tissue cells in clinical stem cell transplants: a potential therapeutic model?
    Martin Korbling
    University of Texas, Department of Stem Cell Transplantation and Cellular Therapy, Unit 423, M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Regen Med 3:157-64. 2008
    ..How genetic material from circulating cells is acquired by solid-organ tissue cells is debated. The purpose of this study was to provide clinical evidence for cell fusion between circulating cells and solid-organ tissue cells...
  3. ncbi request reprint Recombinant human granulocyte-colony-stimulating factor-mobilized and apheresis-collected endothelial progenitor cells: a novel blood cell component for therapeutic vasculogenesis
    Martin Korbling
    Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Transfusion 46:1795-802. 2006
    ..This study provides clinical data on the availability of circulating EPCs at steady state and after recombinant human granulocyte-colony-stimulating factor (rHuG-CSF) mobilization and their collection by leukapheresis...
  4. ncbi request reprint Adult stem cells for tissue repair - a new therapeutic concept?
    Martin Kørbling
    Department of Blood and Marrow Transplantation, University of Texas M D Anderson Cancer Center, Houston 77030, USA
    N Engl J Med 349:570-82. 2003
  5. ncbi request reprint Hepatocytes and epithelial cells of donor origin in recipients of peripheral-blood stem cells
    Martin Korbling
    Departments of Blood and Marrow Transplantation, University of Texas M D Anderson Cancer Center, Houston 77030, USA
    N Engl J Med 346:738-46. 2002
    ..Bone marrow contains stem cells with the potential to differentiate into mature cells of various organs. We determined whether circulating stem cells have a similar potential...
  6. ncbi request reprint Donor lymphocyte apheresis for adoptive immunotherapy compared with blood stem cell apheresis
    M Korbling
    The University of Texas M D Anderson Cancer Center, Division of Medicine, Department of Blood and Marrow Transplantation, Houston, Texas 77030, USA
    J Clin Apher 16:82-7. 2001
    ..leukemia (GVL) effect after allogeneic stem cell transplantation, while lowering the incidence and severity of graft-vs.-host disease (GVHD)...
  7. ncbi request reprint Peripheral blood stem cell versus bone marrow allotransplantation: does the source of hematopoietic stem cells matter?
    M Korbling
    Department of Blood and Marrow Transplantation, University of Texas MD Anderson Cancer Center, Houston 77030, USA
    Blood 98:2900-8. 2001
    ....
  8. ncbi request reprint Allogeneic transplantation for recurrent or refractory non-Hodgkin's lymphoma with poor prognostic features after conditioning with thiotepa, busulfan, and cyclophosphamide: experience in 44 consecutive patients
    K van Besien
    Department of Hematology, University of Texas, M D Anderson Cancer Center, Houston, USA
    Biol Blood Marrow Transplant 3:150-6. 1997
    ....
  9. ncbi request reprint Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies
    I F Khouri
    Department of Hematology, University of Texas M D Anderson Cancer Center, Houston 77030, USA
    J Clin Oncol 16:2817-24. 1998
    ....
  10. ncbi request reprint Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma
    I F Khouri
    Department of Hematology, The University of Texas, M D Anderson Cancer Center, Houston 77030, USA
    J Clin Oncol 16:3803-9. 1998
    ..After four courses, patients were consolidated with high-dose CY, total-body irradiation, and autologous or allogeneic blood or marrow stem-cell transplantation...
  11. ncbi request reprint Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: an intensive regimen for the treatment of multiple myeloma
    A Shimoni
    Department of Blood and Bone Marrow Transplantation, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA
    Bone Marrow Transplant 27:821-8. 2001
    ..TBC merits further study in these subgroups and comparison with alternative regimens in prospective studies is warranted...
  12. ncbi request reprint Allogeneic hematopoietic transplantation for mantle-cell lymphoma: molecular remissions and evidence of graft-versus-malignancy
    I F Khouri
    Department of Blood and Marrow Transplantation, University of Texas, M D Anderson Cancer Center, Houston, USA
    Ann Oncol 10:1293-9. 1999
    ..We report preliminary results suggestive of a graft-versus-lymphoma effect in such patients post allogeneic hematopoietic transplantation...
  13. ncbi request reprint Allogeneic blood progenitor cell collection in normal donors after mobilization with filgrastim: the M.D. Anderson Cancer Center experience
    P Anderlini
    Department of Hematology and Pediatric Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Transfusion 39:555-60. 1999
    ..Information on the safety and efficacy of allogeneic peripheral blood progenitor cell (PBPC) collection in filgrastim-mobilized normal donors is still limited...
  14. ncbi request reprint Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality
    I F Khouri
    Department of Blood and Marrow Transplantation, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Blood 98:3595-9. 2001
    ..Further studies are warranted to compare nonablative allogeneic hematopoietic transplantation with alternative treatment strategies...
  15. ncbi request reprint Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation
    D Przepiorka
    Departments of Blood and Marrow Transplantation, Biomathematics, Laboratory Medicine and Pathology, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Blood 94:1465-70. 1999
    ..GVHD prophylaxis and CD34(+) cell dose are independent risk factors for acute GVHD after allogeneic blood stem cell transplantation...
  16. ncbi request reprint Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma
    D Przepiorka
    Department of Blood and Marrow Transplantation, University of Texas, M D Anderson Cancer Center, Houston, USA
    Ann Oncol 10:527-32. 1999
    ....
  17. doi request reprint Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT
    S O Ciurea
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Bone Marrow Transplant 45:429-36. 2010
    ..Patients with overt relapse fared poorly and require novel treatment strategies...
  18. ncbi request reprint Controlled trial of filgrastim for acceleration of neutrophil recovery after allogeneic blood stem cell transplantation from human leukocyte antigen-matched related donors
    D Przepiorka
    Baylor College of Medicine, Center for Cell and Gene Therapy, The University of Texas M D Anderson Cancer Center, 6565 Fannin Street, Houston, TX 77030, USA
    Blood 97:3405-10. 2001
    ..It can be concluded that the administration of filgrastim after allogeneic blood stem cell transplantation shortens the time to neutrophil recovery. (Blood. 2001;97:3405-3410)..
  19. ncbi request reprint Extracorporeal photopheresis therapy in the management of steroid-refractory or steroid-dependent cutaneous chronic graft-versus-host disease after allogeneic stem cell transplantation: feasibility and results
    N Apisarnthanarax
    Department of Dermatology, MD Anderson Cancer Center, Houston, TX, USA
    Bone Marrow Transplant 31:459-65. 2003
    ..However, most patients continue to require at least some chronic therapy and cGVHD-related morbidity and mortality remain high...
  20. ncbi request reprint A comparative study of once-daily versus twice-daily filgrastim administration for the mobilization and collection of CD34+ peripheral blood progenitor cells in normal donors
    P Anderlini
    Department of Blood and Marrow Transplantation and Laboratory Medicine, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Br J Haematol 109:770-2. 2000
    ..There was no statistically significant difference in the apheresis yield of CD34+ PBPCs (x 106) per kg recipient weight (5.6 +/- 3.3 vs. 5.6 +/- 4.3; P = 0.94) and per litre of blood processed (30 +/- 17.2 vs. 30.4 +/- 19.5; P = 0.92)...
  21. ncbi request reprint Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation
    A Shimoni
    Department of Blood and Bone Marrow Transplantation, University of Texas, M.D. Anderson Cancer Center, Houston 77030, USA
    Biol Blood Marrow Transplant 7:568-75. 2001
    ..This strategy is associated with durable complete remissions and a low rate of complications and therefore merits further investigation in larger-scale comparative trials...
  22. ncbi request reprint Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer
    N T Ueno
    Department of Blood and Marrow Transplantation, University of Texas M D Anderson Cancer Center, Houston 77030, USA
    J Clin Oncol 16:986-93. 1998
    ..To evaluate the feasibility of allogeneic peripheral-blood progenitor-cell (PBPC) transplantation and to assess graft-versus-tumor effects in patients with metastatic breast cancer...
  23. ncbi request reprint Decitabine with allogeneic peripheral blood stem cell transplantation in the therapy of leukemia relapse following a prior transplant: results of a phase I study
    F Ravandi
    Department of Hematology, University of Texas MD Anderson Cancer Center, Houston 77027, USA
    Bone Marrow Transplant 27:1221-5. 2001
    ..Current response data should encourage further study of this drug, either alone or in combination with other agents, for treatment of relapsed acute leukemia after an allogeneic transplant...
  24. ncbi request reprint Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies
    L Lekakis
    Department of Blood and Marrow Transplantation, UT MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    Bone Marrow Transplant 38:421-6. 2006
    ..Two patients are alive and disease free; 4-year actuarial survival is 33 versus 0% for patients transplanted in remission versus in relapse. We concluded that disease status was the main determinant of treatment failure in this study...
  25. ncbi request reprint Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma
    S Giralt
    Department of Blood and Bone Marrow Transplantation, University of Texas MD Anderson Cancer Center, Houston 77030, USA
    Bone Marrow Transplant 30:367-73. 2002
    ....
  26. ncbi request reprint Long-term follow-up of normal peripheral blood progenitor cell donors treated with filgrastim: no evidence of increased risk of leukemia development
    P Anderlini
    Department of Blood and Marrow Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 4095, USA
    Bone Marrow Transplant 30:661-3. 2002
    ..Although the sample size is small and the follow-up duration is limited, these data suggest that exposure to filgrastim is not associated with any notable risk of leukemia development in PBPC donors...
  27. ncbi request reprint Circulating stem cells and tissue repair
    B Hennessy
    Department of Bioimmunotherapy and Blood and Marrow Transplantation, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Panminerva Med 46:1-11. 2004
    ..There is increasing evidence that we can manipulate in vivo circulating adult stem cells to repair or regenerate solid organ tissue, which offers potential clinical benefit in the treatment of many hereditary and acquired diseases...
  28. ncbi request reprint Umbilical cord blood-derived cells for tissue repair
    M Korbling
    Department of Blood and Marrow Transplantation, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cytotherapy 7:258-61. 2005
    ..The potential therapeutic use of UCB cells for tissue repair is, however, limited by a low total stem cell number available and by HLA-disparity...
  29. ncbi request reprint Adult stem cells and tissue repair
    M Korbling
    Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 423, Houston, TX 77030, USA
    Bone Marrow Transplant 32:S23-4. 2003
    ..Using adult stem cells to generate or repair solid organ tissue obviates the immunologic, ethical, and teratogenic issues that accompany embryonic stem cells...
  30. ncbi request reprint A mathematical model of haemopoiesis as exemplified by CD34 cell mobilization into the peripheral blood
    M N Obeyesekere
    Department of Biostatistics and Applied Mathematics, Unit 237, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA
    Cell Prolif 37:279-94. 2004
    ....
  31. ncbi request reprint Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma
    C Hosing
    Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Ann Oncol 13:450-9. 2002
    ....